Abstract: The present application discloses a method for allocating processing task of insurance service, a computer readable storage medium, a terminal device and an apparatus. This method comprises: determining a processing task to be allocated and an insurance service corresponding to the processing task; acquiring an evaluation factor of the insurance service; determining a processing authority level required by the processing task according to the acquired evaluation factor; determining institution authority levels of various insurance institutions according to the acquired evaluation factor and preset institution factors of the various insurance institutions; determining a first insurance institution entitled to handle the processing task according to the processing authority level and the institution authority levels; and allocating the processing task to the first insurance institution according to a preset allocation rule.

Abstract: The present invention relates to the design, fabrication and applications of three-dimensional (3D) bioreactor for cell expansion and cell secreted substance production. The bioreactors have relatively low levels of potentially cytotoxic compounds, can be coated with substituted or unsubstituted poly(p-xylene) type coatings and can also be separately formed from liquid crystal photopolymerizable monomers.

Abstract: Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio “?” value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid. Methods of detecting blood in a sample, such as a fluid sample, and kits for performing the methods, are also provided.

Abstract: The present invention relates to the application of a three-dimensional (3D) bioreactor for T-cell expansion for immunotherapy.

Abstract: Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio “?” value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

Abstract: Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio “?” value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

Abstract: PEGylated polyhemoglobin nanocapsules are provided, wherein the nanocapsules each include a core including polyhemoglobin, a polymer shell encapsulating the core, a polydopamine layer on an exterior surface of the shell, and poly(ethylene glycol) adhered by the polydopamine to the shell. A method of forming PEGylated polyhemoglobin nanocapsules includes extracting hemoglobin from red blood cells. The method further includes polymerizing the hemoglobin to provide polyhemoglobin. The polyhemoglobin is then encapsulated in a plurality of polymer shells to form a plurality of polyhemoglobin nanocapsules. In addition, a polydopamine is deposited on an external surface of the polyhemoglobin nanocapsules. Poly(ethylene glycol) is then adhered to the polyhemoglobin nanocapsules with the polydopamine to provide a plurality of PEGylated polyhemoglobin nanocapsules.

Abstract: Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio “?” value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

Abstract: Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio “?” value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

Abstract: A method, device, terminal and storage medium for data verification is disclosed. The method includes: obtaining package information to be verified and a corresponding definer of the package information; calculating a deviation degree of the package information according to a predetermined matching algorithm based on an operation authority and a historical definition data of the definer, the deviation degree reflects an accuracy of the package information defined by the definer; outputting a prompt message to prompt the definer to verify the package information if the deviation degree is greater than a preset deviation standard value, so that a preliminary verification to the package information newly defined by the salesman is realized; the salesman is further prompted to check the package information according to the verification results, thereby effectively reducing the error rate of package information and the impact of incorrect definer on sales amount.

Abstract: A method, device, terminal, and storage medium for amending prompt. The method comprises: when an operation that a specified product is amended is detected, obtaining attribute information of a current amendment; inquiring a relevance model according to the specified product and the attribute information, so as to obtain relevant products of the specified product and relevant attribute information of the attribute information; and outputting prompt information, so as to prompt the user whether to amend the relevant products and the relevant attribute information synchronously. In this way, the user can obtain relevant products or attribute information during an amending process of an insurance product, amending operations of the user are effectively facilitated, the amending efficiency is improved, and it is convenient to reduce the probability of missed amendments or mistaken amendments of insurance products.

Abstract: Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio “?” value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

Abstract: The present disclosure relates to the design, fabrication, and applications of a three-dimensional (3D) bioreactor for cell expansion and cell secreted substance production. The bioreactor is composed of non-random interconnected voids providing a continuous three-dimensional surface area for cell adherence and growth.

Abstract: The present disclosure is directed at a process to form bone grafting material. One may provide a porous collagen scaffold and insert the scaffold into a perfusion chamber of a perfusion flow system. This may then be followed by continuously providing a mineralization perfusion fluid flow through the scaffold at a flow rate to provide dynamic intrafibrillar mineralization of the scaffold and form a collagen/hydroxyapatite composite scaffold. One may optionally provide the scaffold with bone tissue forming cells and then deliver a perfusion fluid including oxygen and one or more nutrients through the collagen/hydroxyapatite composite scaffold and to the bone tissue forming cells at a flow rate such that the bone tissue forming cells remodel the collagen/hydroxyapatite composite scaffold and form a bone tissue extracellular matrix. The bone tissue extracellular matrix may then be decellularized to form an acellular bone repair scaffold.

Abstract: A hybrid tissue scaffold is provided which comprises a porous primary scaffold having a plurality of pores and a porous secondary scaffold having a plurality of pores, wherein the secondary scaffold resides in the pores of the primary scaffold to provide a hybrid scaffold. The pores of the porous primary scaffold may have a pore size in a range of 0.50 mm to 5.0 mm, and the pores of the porous secondary scaffold may have a pore size in a range of 50 ?m to 600 ?m. The primary scaffold may provide 5% to 30% of a volume of the hybrid scaffold.

Abstract: A engineered tissue implant comprising a perfusion chamber formed with a biocompatible flexible tubular member having a wall defining an internal fluid flow passage and a porous scaffold within the fluid flow passage of the tubular member, the porous scaffold arranged such that, in a presence of a perfusion fluid, the perfusion fluid will flow through the porous scaffold and be inhibited from flow between the porous scaffold and the wall of the tubular member. The engineered tissue implant may be understood as a transplantable cell construct or as an implantable bioreactor for cell growth both in vitro and/or in vivo. A method to provide tissue for reconstruction may comprise forming the engineered tissue implant containing a scaffold, introducing and seeding cells to the scaffold, introducing a perfusion fluid to the scaffold which flows through the fluid flow passage and scaffold, proliferating the cells within the scaffold and forming blood vessels within the scaffold.

Abstract: The present disclosure is directed at a process to form bone grafting material. One may provide a porous collagen scaffold and insert the scaffold into a perfusion chamber of a perfusion flow system. This may then be followed by continuously providing a mineralization perfusion fluid flow through the scaffold at a flow rate to provide dynamic intrafibrillar mineralization of the scaffold and form a collagen/hydroxyapatite composite scaffold. One may optionally provide the scaffold with bone tissue forming cells and then deliver a perfusion fluid including oxygen and one or more nutrients through the collagen/hydroxyapatite composite scaffold and to the bone tissue forming cells at a flow rate such that the bone tissue forming cells remodel the collagen/hydroxyapatite composite scaffold and form a bone tissue extracellular matrix. The bone tissue extracellular matrix may then be decellularized to form an acellular bone repair scaffold.

Abstract: The present disclosure is directed at a process to form bone grafting material. One may provide a porous collagen scaffold and insert the scaffold into a perfusion chamber of a perfusion flow system. This may then be followed by continuously providing a mineralization perfusion fluid flow through the scaffold at a flow rate to provide dynamic intrafibrillar mineralization of the scaffold and form a collagen/hydroxyapatite composite scaffold. One may optionally provide the scaffold with bone tissue forming cells and then deliver a perfusion fluid including oxygen and one or more nutrients through the collagen/hydroxyapatite composite scaffold and to the bone tissue forming cells at a flow rate such that the bone tissue forming cells remodel the collagen/hydroxyapatite composite scaffold and form a bone tissue extracellular matrix. The bone tissue extracellular matrix may then be decellularized to form an acellular bone repair scaffold.

Abstract: A hybrid tissue scaffold is provided which comprises a porous primary scaffold having a plurality of pores and a porous secondary scaffold having a plurality of pores, wherein the secondary scaffold resides in the pores of the primary scaffold to provide a hybrid scaffold. The pores of the porous primary scaffold may have a pore size in a range of 0.50 mm to 5.0 mm, and the pores of the porous secondary scaffold may have a pore size in a range of 50 ?m to 600 ?m. The primary scaffold may provide 5% to 30% of a volume of the hybrid scaffold.

Abstract: The present invention provides multi-parameter analysis methods for determining the presence or absence of pre-cancerous or cancerous cells in a cervical sample and for screening cervical abnormality in a cervical sample. The invention also provides an apparatus and automated methods for screening cervical abnormality in a sample. The invention further provides a sampling device and a sample collection assembly for collecting cell samples, including cervical samples.